Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure

University of Aarhus28 enrolled

Overview

The primary objective of this study is to evaluate whether metabolic modulation improves left ventricular function, work capacity, insulin sensitivity and modifies substrate metabolism in chronic heart failure

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Heart Failure

Interventions

acipimoxDRUG

capsule, 250 mg, 4 times daily for 28 days

placeboDRUG

capsule, 250 mg, 4 times daily for 28 days

Eligibility

Sex: ALLMin age: 30 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * EF\<40 % * IHD * NYHA-class II-III. Exclusion Criteria: * pregnancy * severe renal failure * new brady- or tachyArrhythmia * Severe stenotic valvular disease * myocardial infarction within last 6 weeks * insulin treated diabetes mellitus * peptic ulcer * pregnancy or lactating women * allergy towards tested medicine

Locations (1)

Department of Cardiology, Aarhus Universityhospital, Skejby

Aarhus N, Denmark

Outcomes

Primary Outcomes

left ventricular ejection Fraction

Time frame: 4 weeks

exercise capacity

Time frame: 4 weeks

muscular metabolism

Time frame: 4 weeks

Secondary Outcomes

regional left ventricular function

Time frame: 4 weeks

insulin resistance

Time frame: 4 weeks

full body metabolism

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.